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Transport Characteristics Using Nor-Dihydroguaiaretic Acid (NDGA)-Polymerized
Collagen Fibers as a Local Drug Delivery System
Eric Guegan
ABSTRACT
Dexamethasone and dexamethasone 21-phosphate were loaded into NDGApolymerized collagen fibers and release rate studies were performed to calculate their
diffusion coefficients.
Dexamethasone loaded fibers were placed in a PBS solution for specified time
intervals (1, 3, 6, 7, 12, 24, 30, and 48 hours) after which the eluant was removed and
analyzed by capillary zone electrophoresis (CZE). CZE is a tool that can be utilized for
quantitative analysis of chemical compounds. This data was incorporated into
mathematical models to determine the diffusion coefficient. The diffusion coefficient (D)
for dexamethasone in NDGA-polymerized collagen fibers is D = 1.86 x 10-14 m2/s.
Similarly, dexamethasone 21-phosphate loaded fibers were placed into a PBS
solution and analyzed using CZE at these specified intervals (15, 30, 45, 60, and 75
minutes). Applying this data to the mathematical model provided a diffusion coefficient
for dexamethasone 21-phosphate in NDGA-polymerized collagen fibers of D = 2.36 x 1013

m2/s.
In an effort to control drug delivery from these fibers a polylactic-co-glycolic acid

(PLGA) coating was applied to the fibers. This coating helped sustain delivery of
dexamethasone 21-phosphate for over a 100 day period. CZE experiments were again
vi

conducted in conjunction with another mathematical model to characterize release. A
semi steady-state diffusion coefficient was estimated to be D = 4.59 x 10-14 m2/s.

vii

Chapter 1
Background
1.1 Diabetes
Diabetes is a disease that affects the blood glucose levels. These levels are
augmented to a higher state because of a deficiency in insulin production and utilization.
In 2002, the 6th leading cause of death in the United States was diabetes. This disease
afflicted 20.8 million Americans in 2005. Diabetes can cause serious complications in the
human body, and people of similar age with this disease are twice as likely to experience
premature death. Every day 613 Americans will die from this disease. Regrettably, the
cause for diabetes is still unknown; however, genetics and environmental factors such as
health and diet contribute greatly to this disease3.
Diabetes mellitus is a chronic metabolic disorder affecting the way the body uses
glucose. When food is consumed and digested it is broken down into glucose, a simple
sugar that is the main source of energy for the body. Glucose is absorbed into the blood
stream where cells utilize it for energy and growth. However, glucose alone cannot be
absorbed into the cells; it requires the presence of insulin. Insulin is a hormone produced
by the pancreas whose primary function is to help the cells metabolize and use glucose.
During the digestion phase the body produces the appropriate amount of insulin required
to move glucose from the bloodstream to our cells. However, this systemic disease can
limit or cause no insulin production to occur and can even alter the cells response to the
1

insulin. When this happens there is nothing present to fuel the cells or metabolize the
excess glucose, resulting in Hyperglycemia7. This can lead to numerous potential
problems throughout the body (Table 1).

Table 1. The numerous complications diabetics may face4.
Complications
Hypertension
Heart disease and stroke
Diabetic retinopathy, blindness
Diabetic nephropathy, kidney failure
Nervous system disease (digestion
problems, Carpal Tunnel Syndrome, lack
of feeling or pain in appendages, etc…)
Lower-extremity amputations
Pregnancy
Biochemical imbalances can lead to:
Diabetic ketoacidosis
Hyperosmolar (nonketonic) comas

Affects more than 70% of all diabetics
2 to 4 times as likely to experience than
someone who does not have this disease
Leading cause of blindness (ages 20-74)
Leading cause of kidney failure
Affects more than 60% of all diabetics
60% of all cases are diabetics
15-20% increased chance of miscarriage
5-10% will have major birth defects
Acute life threatening events

Since diabetes primarily targets insulin production and influences glucose levels it
is evident that maintaining and monitoring these levels is of the utmost of importance.
There are two main types of blood tests administered: the A1c blood test and selfmonitoring of blood glucose (SMBG) test. Both of these are used to monitor glucose
levels and provide vital results to aid in the adjustment of treatments. The A1c blood test
measures the glycerated hemoglobin percentage. The protein, hemoglobin, is a
component in red blood cells that transfers oxygen from the lungs to the body. The excess
presence of glucose caused from diabetes links up and glycates with the molecules of the
2

hemoglobin. This forms a compound known as HbA1c that can be measured by the A1c
test as a percentage, which shows an average of the glucose control over a two to three
month period7.
The second method, the SMBG test, is self-administrated about two to four times
a day. This provides the patient with a better understanding of how their bodies’ glucose
levels fluctuate. Changes in medicine, diet, stress, physical activity, health, or routines
can alter the state of your blood glucose. By monitoring these levels the diabetic patient
will learn how their body reacts and can make self-adjustments when needed. These daily
results are compared to the physician’s A1c test to see if accuracy is being achieved. This
also allows the physician to see possible trends and to adjust treatments appropriately.
However, both test methods are fairly effective for the monitoring of glucose but
each presents limitations. The A1c is by far the most accurate method of the two but must
be administered by a physician and then sent to a lab for analysis. It is only taken every
two to three months and within this time frame drastic changes in glucose levels may
occur. In most cases SMBG test would pick up these changes; however, studies show that
patient testing techniques are not without error. An estimated 31% of SMBG users, due to
improper testing techniques, have results that vary by 10-20% of the actual glucose value
and 53% perform errors that cause results to be off up to 10%. Furthermore, FDA
guidelines allow glucose meters on the market to vary up to 20% of actual blood glucose
levels. So, with all this variation how accurate are the readings patients are receiving? It
seems a better monitoring technique is needed, one which has the accuracy of the A1c
testing but the frequency of SMBG testing. A technique to monitor glucose levels without
the influence of human error1, 15.
3

1.2 Glucose Sensor
A possible solution to the inadequacies of the SMBG and A1c tests would be to
develop an implantable glucose sensor for the body (figure1). This biosensor would
revolutionize current monitoring techniques and significantly contribute to the control
and understanding of diabetes. Current monitoring techniques use discrete measurement
methods collecting data points from a system that is constantly changing. These test
methods contribute to delays from the acquired level to actual glucose level due to the
setup and test time. Similarly, patterns or rapid fluctuations in the patient’s glucose levels
will not show. To develop an effective means to continuously monitor glucose levels
would be of great benefit to the medical community. Through continuous monitoring of
blood glucose levels diabetics would be able to administer insulin in a timely manner,
knowing precisely when levels are not where they should be. This in itself would be a
great tool furthering the effectiveness of insulin delivery and proactively preventing the
frequencies of attacks from occurring. It is clear there is a need for these sensors, and
there is a potential market. In 2002 the American Diabetes Association reported that U.S.
healthcare costs for diabetes exceeded 132 billion dollars. According to Business
Communications Company Inc. who performed a market study in 2002, predicted that by
2007 glucose monitor market will exceed 8 billion dollars worldwide. Clearly, the need
for improvement is present and with increasing technological advancements an
implantable glucose sensor is a feasible solution.
In general, this sensor will need to be tiny, as it is to be implanted in human
tissue; it will need to provide accurate readings with a rapid response-time; and also be
biocompatible with the human body. Miniaturization is no longer an issue as
4

technological advancements have lead to substantial improvements in sensor designs.
Current glucose sensor elements occupy an area in the range of less than 1mm2. These
sensors can accurately provide continuous response times given that the sensor is intact
and not influenced by outside factors. Furthermore, sensors are becoming increasingly
more biocompatible as our understanding of material properties and the human response
to these increases. However, the body’s greatest ally is the enemy to the biosensor; the
human body’s complex defense and healing mechanisms. This intricate system has lead
to substantial failures in designing an effective implantable glucose sensor.

9

Figure 1. Implantable glucose sensor .

1.3 Sensor Complications
These failures often occur due to the interaction between the biosensor and the
body’s immune system response. There are two reactions that occur when implanting
sensors that contribute to their failure: the implantation process and the foreign body
response. During the implantation phase a wound is created at the surgical site. Various
5

techniques have been studied to minimize tissue and cell damage from surgical incisions
to insertion using small gauge needles. However, all these techniques will contribute to a
certain amount of damage at the insertion site that cannot be avoided. When thinking of
the biosensors’ size one must consider that although it is very small, it is much larger
than the cells and blood capillaries from which it will need to acquire data making
insertion damage inevitable. Consequently, one must minimize the implantation site as
much as possible and ensure the sensor is contaminant free to eliminate risk of infection.
Similarly, one must prevent the body’s defenses from rejecting the sensor. As the body
begins the wound-healing phase, trying to stop loss of blood, prevent infection and
restore function to the injured implantation site; inflammatory cells like neutrophils and
macrophages detect the presence of a foreign body. Since phagocytosis, the breakdown of
foreign objects, is nearly impossible the macrophages form into giant cells encapsulating
the site. The giant cells will form a collagen shell around the implant preventing normal
interaction with the body by isolating it from surrounding tissue. This will lead to chronic
inflammation resulting in potential sensor failure and inaccurate sensor readings.
There is a viable solution to this problem, which deals primarily with the
biocompatibility of materials. Biocompatible materials are ideally ones, which are not
rejected by the body, ones that elicit very little foreign body response and cause little to
no irritation in the body. However, no current implant materials have been developed
that will not induce some sort of biological response. Since this cannot be avoided, the
only answer is to reduce the reaction that will occur. If one can modify the outer layer of
the biosensor to a more tolerable material then there will be less interaction between the
body’s defenses and the device. Essentially, the body would be deceived into accepting
6

the device as normal. However, this is a very complicated task. It would be even more
effective to combine a special outer layer to the sensor, which could lessen the foreign
body response through the use of preventive agents to help the sensor gain acceptance6.

1.4 Control Inflammation by Using a Drug Delivery System
The use of preventive agents could substantially improve the function of the
sensor. By combining the sensor with a drug delivery coating one, could use the
medicinal properties of the agent to prevent the body’s foreign body response. Dr. T.J.
Koob has developed a biocompatible fiber that ideally suits this purpose (figure 2). By
surrounding the sensor with a collagen based nor-dihydroguaiaretic acid (NDGA) fiber
potential negative interaction between the body and sensor could be limited. Using this
fiber as a delivery system an anti-inflammatory agent could be administered by the
process of diffusion. A substantial candidate for this is dexamethasone. This synthetic
glucocorticoid is widely used as an anti-inflammatory and an immunosuppressive drug.
Therefore, surrounding the fiber with dexamethasone loaded NDGA fibers should
provide an effective means for controlling inflammation and drastically increase the life
of the sensor.

7

Figure 2. NDGA collagen fibers.

1.5 Purpose
Now that an effective system has been hypothesized to help extend biosensor
function the mechanisms that control our process must be understood. Diffusion is a
passive transport process where the driving potential is due to the species concentration
gradient. The higher concentration of dexamethasone will diffuse to the lower
concentration until a balance is achieved (figure 21 appendix. page 51). Diffusion will
occur until the drug is depleted from the fiber8. The dexamethasone loaded NDGA
collagen fibers will administer the drug at a specific rate. This diffusion coefficient will
help one understand how much of the drug could potentially be delivered into the body
for a certain length of time. However, calculations of this rate have never been performed
in this media. This paper aims to illustrate a novel drug delivery system and model
transport characteristics for three different cases presenting the various analytical and
8

experimental techniques performed to obtain these rates. The three cases examined were:
i.) dexamethasone diffusing through the NDGA collagen fiber ii.) dexamethasone-21
phosphate disodium diffusing through NDGA collagen fibers iii.) dexamethasone-21
phosphate disodium diffusing through a polylactic-co-glycolic acid (PLGA) coating that
surrounds the fiber. Understanding these rates will help to optimize an effective drug
deliver system.

9

Chapter 2
NDGA Collagen Fibers
2.1 Background
In attempt to produce a material for use in tendon repair, Dr. Thomas J. Koob
developed NDGA collagen based fibers. These fibers were created with similar
mechanical properties to the actual human tendon, modeling an elastic solid. More
significantly to this research, the fibers are biologically based and biocompatible10; a key
factor in their potential use as a sensor coating and drug delivery tool. The main
component of these fibers is collagen, a chemical protein found throughout the body that
aids in strengthening and connecting tissues. Since this protein is found throughout the
body it is a prime candidate as a potential biomaterial. Extracted fetal bovine collagens at
37°C in physiological buffers will re-nature into collagen fibrils (figure 3). These
synthetic fibrils are weak because native cross-linking pathways do not manifest in vitro
formation. A cross-linking agent is needed for the collagen fibers to increase the tensile
strength and to lower the potential inflammatory response. The anti-oxidant, NDGA
meets these criteria (figure 4). NDGA is a di-catechol extracted from the creosote bush
and when cross-linked resolved strength and biocompatibility issues11.
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Figure 3. SEM image of two NDGA collagen fibers side by side.

Figure 4. 10x magnification of H & E stained cross-section of implanted fibers at 6 weeks. These were
implanted in the paravertebral musculature of rabbits. It is evident that the control fiber (non cross-linked
collagen fiber) has well-organized capsules of cells surrounding it. It is also fragmented and has begun to
degrade. The NDGA fiber has barely any encapsulating cells surrounding it, with the exception of the right
10
corner. It is completely intact except for fragmentation that was caused during sectioning .

Any biomaterial incorporated into a host must not elicit harm to the body or cells.
However, during the fabrication process, NDGA and residual products from cross-linking
were found to be cytotoxic in vitro. However, by washing the fibers in 70% ethanol
cytotoxicity can be eliminated12. To ensure that non-cytotoxic and biologically based
biocompatible fibers are fabricated, an intricate protocol must be followed.
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2.2 Fiber Fabrication Process
The fiber fabrication process (figure 23 appendix, page 56) is a very delicate and
intricate procedure. It is essential to follow the required steps to produce high strength,
biocompatible fibers. The entire process takes four days and can be broken up into daily
procedures. Refer to appendix (Detailed Fiber Fabrication Protocol, page 53) for a more
detailed procedure.
The fibers were made using purified pepsin-solubilized type I fetal bovine tendon
collagen. The 0.13% w/v collagen solution was placed in 0.32-ml/cm dialysis tubing and
then washed every 30 minutes in de-ionized water for at least 7 hours. The tubing
assemblies were then transferred to a PBS solution of pH level 7.4 and incubated at 37°C
for 16 hours. This extrusion process permits the collagen to re-nature and promotes fibril
alignment. Following this step, the fibers were then hung dry; strengthening the
weakened fibers. Once the fibers are dry, NDGA cross-linking can occur. Oxidized
sodium phosphate buffer, having a pH level of 9.0, is combined with NDGA (Cayman
Chemical, Ann Arbor, MI) to form the cross-linking agent. The amount of oxygen
present accelerates the cross-linking reaction. The fibers are then agitated in this NDGA
solution overnight. The final day encompasses washing and drying the NDGA treated
fibers. The fibers are washed in 70% ethanol to remove any un-reacted, soluble NDGA
intermediates. The procedure is sufficiently repeated to ensure all unbound NDGA is
removed. The fibers are finally straightened and hung vertically in tension to dry
overnight, completing the fabrication process.
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2.3 Dexamethasone Loading
With the fabrication process complete the fibers are ready to be loaded with a
drug agent. The drug loading procedure is fairly simple and could potentially be applied
to other drug agents. In the first case, ten dried fibers were loaded with dexamethasone.
These samples (diameter of 0.08 mm) were cut into 10 mm lengths and placed into 1.5 ml
tubes. These tubes contained 200 μl of 10 mg/ml of dexamethasone (SIGMA, St. Louis,
MO) in a 70% ethanol solution (10 fibers/tube, number of tubes, n = 10). The fibers were
incubated in this mixture for 18 hours at room temperature. The solution was then
removed and the fibers were allowed to air dry for 24 hours. Once dried, the fibers were
washed in 200 μl of PBS, with pH level of 7.4, to remove any residual dexamethasone
left from drying. The fibers were then incubated at 25°C in 200 μl of PBS in the dark, as
it is light sensitive. The PBS was removed at specific time periods (1, 3, 6, 7, 12, 24, 30,
and 48 hours) and replaced with fresh PBS. This removed dexamethasone was analyzed
by Capillary Zone Electrophoresis (CZE) for drug elution amounts (refer to ch.3).

2.4 Dexamethasone 21-phosphate Loading
In the second case, ten dried fibers of length 10 mm and diameter of 0.08 mm
were placed into a 1.5 ml tubes. These tubes contained 200 μl of 10 mg/ml of
dexamethasone 21-phosphate disodium salt (SIGMA, St. Louis, MO) in a 3% acetic acid
solution (10 fibers/tube, number of tubes, n = 10). The fibers were then incubated at room
temperature for 18 hours in this solution. The mixture was discarded and the fibers were
air dried for 24 hours. The dried fibers were then washed with PBS, with a pH level of
7.4, to remove any residual dexamethasone 21-phosphate not incorporated into the fibers.
13

The fibers were then stored in the dark at 25°C, in 200 μl of PBS. The PBS was removed
at specific time intervals (15, 30, 45, 60, and 75 minutes) and analyzed on the CZE. Fresh
PBS replaced the removed solution, which was analyzed on the CZE for dexamethasone
21-phosphate content (refer ch.3).

2.5 PLGA Coating of NDGA Collagen Fibers
In the third examined case dexamethasone 21-phosphate loaded fibers (n = 15)
were coated with PLGA (figure 22 appendix, page 51). To coat the fibers, 0.5g of PLGA
crystals, which were stored at –20°Celsius, were dissolved in 1g of chloroform. The
chloroform had a purity of 99% and is anhydrous. Place the solution on a rocker for at
least 2 hours to ensure complete PLGA crystal breakdown. Allow the solution to sit
overnight to dissipate any air bubbles from the mixture. On the following day, dip coat
the fibers in PLGA (50:50) in chloroform (PLGA/chloroform = 54%) uniformly. Remove
them from the solution and hang them to air dry at 25°C for 5 days. This will provide a
PLGA coating to the fibers with an average diameter of 0.306 mm (n = 30). The coated
fibers were then incubated in 200 μl of PBS (3 fibers/tube). The PBS was removed at
varying time intervals and examined on the CZE for dexamethasone 21-phosphate
content (refer to ch.3). The PBS was replaced with fresh PBS after every analysis.

14

Chapter 3
Capillary Zone Electrophoresis
Capillary zone electrophoresis (CZE) is a tool that can be utilized for quantitative
analysis of chemical compounds. The system has the ability to separate analytes based on
their charge and size. The CZE machine usually consists of two reservoirs and a capillary
filled with a homogeneous buffer solution. Supplying a high-voltage across the capillary
creates an electric field. This electric field produces an electro-osmotic flow in the
capillary causing the cations in the solvent to migrate towards the cathode. This migration
also allows separation of the chemical compound because of the electrophoretic mobility
of the analyte. Using various wavelengths, depending on your sample, the migration rates
can be detected and quantified using UV methods of detection. This data is then sent to a
computer and displayed as an electropherogram, which displays the response as a
function of time. The output is displayed as peaks based of the analytes retention times.
The consequential profile provides a very fast, highly efficient separation method.
By taking the drug loaded fibers and analyzing them in vitro, in sink conditions,
concentration levels can be found. Since the fibers are in sink conditions, the PBS washes
described earlier, provide a solution containing PBS and the eluted dexamethasone agents.
Using the CZE machine the amount of eluted drug can be calculated at each time interval.
The PBS eluant was analyzed on a Dionex Capillary Electrophoresis System I. Using a
sodium borate buffer (10 mM of sodium borate, 50 mM of boric acid, pH 8.0) the eluant
15

was diluted (2 fold). It was then loaded from a height of 50 mm for 10 s by gravity into a
75 μm inner diameter x 80 cm long hollow glass capillary. This capillary was then
electrophoresed at 20,000 V. Dexamethasone agents can be detected at 246 nm13. Prior to
loading samples, calibration of the CZE was performed for dexamethasone and
dexamethasone 21-phosphate. Standards were dissolved directly into the CZE buffer at
increasing concentrations providing a relationship between peak area output and
concentration. Running each of the experimental samples in the CZE provided the elution
amounts determined from peak area. This provided data for the amount of
dexamethasone and dexamethasone-21 phosphate released with respect to each time
interval.

16

Chapter 4
Mathematical Model
4.1 Transient Mathematical Model
From a research standpoint, it is vital to understand how various chemicals and
agents react within other media. When there is a different species concentration in a
mixture, mass transfer will occur. The primary mechanism governing this mass transfer
or drug release from the fibers is diffusion. In the first two examined cases fibers were
placed into a well-stirred reservoir of PBS. This represents a sink condition as would
occur in the body. The sink condition ensures a balance will not be achieved between
concentrations inside and outside the fibers, as the volume is sufficiently large allowing
complete diffusion. To understand this better one can use mathematical models to help
illustrate the occurring process. To begin a few assumptions must be made to properly
model the specified case. The formations of the fibers are solid and uniform in nature,
meaning there is no other material inside the fibers to warrant a composite case. The
fibers are cylindrical in formation having a length of 10 mm. The hydrated radius of the
fibers is on average 0.058 mm. The length to radius ratio is sufficiently large enough to
assume the case of diffusion through a cylinder of infinite length. Secondly, this ratio also
means diffusion through the cylinder will happen radially; diffusion with respect to
length is insubstantial. Also, diffusion here is a transient process, thus is time dependent.
Based off these assumptions and simplifications, a governing equation can be formulated
17

that describes the concentration of a diffusing substance from a long cylinder with a
uniform distribution under steady-state conditions:

⎡ ∂ 2 c 1 ∂c ⎤
∂c
= D⎢ 2 +
⎥
∂t
r ∂r ⎦
⎣ ∂r

(1)

Here, c is the concentration of the drug in the fiber, t is the time following
immersion into the reservoir, D is the diffusion coefficient of the drug in the fiber, and r
is the radial distance within the fiber. Certain boundary conditions must be assumed to
solve this equation: 1) the drug distribution is initially uniform in the fiber (c = ci at t = 0
for 0 < r < R where R is the radius of the fiber and ci is the initial concentration); and 2)
the drug concentration at the surface of the fiber is zero throughout the release (c = 0 for t
> 0 at r = R). The solution for equation (1) is19:

c(r , t ) =

2ci
R

∞

∑α
n =1

J 0 (α n r )
2
exp(−α n Dt )
n J 1 (α n R )

(2)

This solution provides an expression where concentration is a function of radial distance
and time. This allows concentration profiles to be formulated for dexamethasone and
dexamethasone 21-phosphate eluted from the NDGA collagen fibers.
The amount of diffusing substance per unit area, Mt, which has left the cylindrical
fibers in time, t equals:
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⎛ ∂c ⎞
M t = − ∫ D⎜ ⎟ dt
⎝ ∂r ⎠ r = R
0
t

(3)

If M∞ is the amount of diffusing substance per unit area that is left as t approaches
infinity, then for short times this equation becomes:

Mt
4 ⎛ Dt ⎞
= ⎜ ⎟
M∞ R ⎝ π ⎠

0.5

(4)

The amount, M∞, is also the same as the initial amount loaded into the fibers. The amount,
M∞, is also the same as the initial amount loaded into the fibers. By combining equation
(4) with the slope from experimental data plots for Mt/M∞ vs. t1/2 (cumulative drug
release versus the square root of time), the diffusion coefficient, D, can be calculated5.

4.2 Composite Mathematical Model
For the 3rd case in which diffusion occurs from the NDGA fibers through the
PLGA membrane, a different mathematical model was used. Since the PLGA coating
degrades with time, a steady diffusion coefficient cannot be calculated using the
previously mentioned method. Instead, an analysis must be used that looks at each time
interval independently to solve for a time dependent diffusion coefficient.
This model uses the assumption that the PLGA coating is the main factor
controlling diffusion of dexamethasone 21-phosphate; the NDGA collagen fiber acts only
as a storage vessel for the drug. This assumption is valid as the diffusion rate for
19

dexamethasone 21-phosphate in the fiber is much greater than in PLGA, which will be
discussed later in chapter 5. To solve for the time dependent diffusion rate, each time
interval was viewed as an individual diffusion case. Since each time interval was
relatively short, a quasi-steady-state assumption was made. The mathematical model was
assumed to be for a hollow cylinder of infinite length under steady state conditions with
constant drug concentrations on each surface:

0=

∂ 2 c 1 ∂c
+
∂r 2 r ∂r

(5)

Two boundary conditions were assumed here: 1) the inner surface of the PLGA coating
has a concentration equal to the fibers concentration (c = ci at r =Ri where ci is the
concentration in the fiber and Ri is the inner radius, that of the fiber); and 2) the outer
surface of the PLGA coating has a concentration (c = ce at r = Re where Re is the outer
radius of the coated fiber and ce is the concentration in the PLGA coating ) (see figure 5).
Applying these boundary conditions and solving equation (5) leaves an expression for
concentration as a function of radius:

⎛ r
(ce − ci ) ln⎜⎜
⎝ Re
c(r ) = ce +
⎛R ⎞
ln⎜⎜ e ⎟⎟
⎝ Ri ⎠

⎞
⎟⎟
⎠

(6)
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Figure 5. Diagram of the fiber and the model parameters.

Fick’s 1st Law, denoted below, relates the rate of diffusion to the concentration gradient
as the driving force behind mass transfer.

J = −D

dc
dr

(7)

Here, J represents mass flux. This expression can be related to the fibers geometry
through the cross-sectional area, A.

M = JA = − D

dc
A
dr

(8)

By integrating equation (8) with respect to time, an expression for the amount of
diffusing substance, Mt, which diffuses through the length, L, of the cylindrical fibers in
time, t, can be obtained:
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⎛d
⎞
M t = −2πRe LD ⎜ c(r ) ⎟ t
⎝ dr
⎠ r = Re

(9)

Taking the derivative of equation (6) provides an expression for:

d
c(r ) =
dr

c e − ci
⎛R ⎞
ln⎜⎜ e ⎟⎟ Re
⎝ Ri ⎠

(10)

If we assume perfect sink conditions, the concentration in the PLGA membrane will go to
zero. Applying this simplification to equation (10) and substituting this new expression
into equation (9) yields:

Mt =

2πLDci t
⎛R ⎞
ln⎜⎜ e ⎟⎟
⎝ Ri ⎠

(11)

This formula can be re-arranged into a numerical expression to calculate the diffusion
coefficient at each time interval. The fibers concentration, ci, will now be a function of
the total concentration left in the fiber at the specific time being examined. Similarly, Mt
will be a function for the amount of diffusing substance at each time. Lastly, the time, t,
will be the time period. This leads to an expression for the individual diffusion coefficient
at each specific elution period:
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D(t ) =

⎛R
Mt
ln⎜⎜ e
2πLci (Δt ) ⎝ Ri

⎞
⎟⎟
⎠

(12)

Refer to appendix (Program Diffusion through PLGA membrane Program, page 86) for
calculations and for a more in depth derivation of formulas.
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Chapter 5
Dexamethasone Loaded Fiber Results

Using the CZE machine a standard curve for dexamethasone was created by
dissolving varying concentrations of dexamethasone in PBS. The different concentrations
were diluted (2 fold) into a sodium borate buffer and then electrophoresesed as described
in chapter 3. The obtained peak areas provided a linear relationship for concentration
(figure 6).
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Figure 6. Standard curve for dexamethasone.

The dexamethasone-loaded fibers were placed in a PBS solution for specified
time intervals (1, 3, 6, 7, 12, 24, 30, and 48 hours). After each incubation period the
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eluant was removed and analyzed using CZE. This provided an accurate method for
determining the dexamethasone content, which was eluted into the PBS solution at each
period (figure 7).
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Figure 7. CZE data obtained from each incubation time.

Using the standard curve (figure 6) with the above figure’s data provides a direct
correlation between time and concentration levels. The peak areas for each sample were
converted to their equivalent concentration using this relationship (figure 8).
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Figure 8. Relationship between dexamethasone concentration and time.

Simply taking the corresponding concentration at each time interval and adding
the following concentration can form a cumulative relationship. This shows the
cumulative release of dexamethasone concentration for each time until depletion (figure
9). The outlying bars represent standard deviation. Refer to appendix (Program
Dexamethasone – Concentrations, page 57) for calculations.
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Figure 9. Cumulative concentration release against time for dexamethasone.

The fibers on average were loaded with a concentration of 0.021 mg/ml of
dexamethasone as verified by CZE. Based off the release data the fiber segments were
loaded with 4.2 μg of dexamethasone. Knowing the initial concentration allows the
previous figure to be converted to a cumulative mass release versus time plot. The
cumulative mass release plot is then taken against the square root of time (figure 10).
This ensures the data is in the proper format to apply equation (4) from the mathematical
model. Taking the slope for the short times from this plot satisfies,

slope =

Mt M∞
t

which allows one to solve for the diffusion coefficient.
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Figure 10. (A) The cumulative percent of dexamethasone released per fiber into PBS versus time.
(B) The cumulative percent of dexamethasone released per fiber into PBS versus the square root
of time. Dashed line indicates the slope for short times.

The rather large standard deviation is probably because of the insolubility of
dexamethasone in PBS. The first 6 hours of release of dexamethasone was linear with
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respect to the square root of time. Approximately 60% of the drug was released in the
first 3 hours; by 6 hours nearly 77% had been released. Using the slope the diffusion
coefficient was estimated to be D = 1.86 x 10-14 m2/s. Refer to appendix (Program
Diffusion Coefficient for Dexamethasone Calculations, page 84).
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Chapter 6
Dexamethasone 21-phosphate Loaded Fiber Results

Using the CZE machine a standard curve for dexamethasone 21-phosphate was
created by dissolving varying concentrations of dexamethasone 21-phosphate in PBS.
The different concentrations were diluted (2 fold) into a sodium borate buffer and then
electrophoresesed as described in chapter 3. The obtained peak areas provided a linear
relationship for concentration (figure 11).
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Figure 11. Standard curve for dexamethasone 21-phosphate.

The dexamethasone 21-phosphate loaded fibers were placed in a PBS solution for
specified time intervals (15, 30, 45, 60, and 75 minutes). After each incubation period the
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eluant was removed and analyzed using CZE. This provided an accurate method for
determining the dexamethasone 21-phosphate content, which was eluted into the PBS
solution at each period (figure 12).
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Figure 12. CZE data obtained from each incubation time for dexamethasone 21-phosphate.

Using the standard curve (figure 11) with the above figure’s data provides a direct
correlation between time and elution concentration levels. The peak areas for each
sample were converted to their equivalent concentration using this relationship (figure
13).
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Figure 13. Relationship between dexamethasone 21-phosphate concentration and time.

Taking the corresponding concentration at each time interval and adding the
following concentration a cumulative relationship can be formed. This shows the
cumulative release of dexamethasone 21-phosphate concentration for each time until
depletion (figure 14). The outlying bars represent standard deviation. Refer to appendix
(Program Dexamethasone 21-phosphate Concentrations, page 63) for calculations.
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Figure 14. Cumulative concentration release against time for dexamehatsone 21-phosphate.

The fibers on average were loaded with a concentration of 0.222 mg/ml of
dexamethasone 21-phosphate as verified by CZE. Based off the release data the fiber
segments were loaded with 44.4 μg of dexamethasone 21-phosphate. Knowing the initial
concentration allows the previous figure to be converted to a cumulative mass release
versus time plot. The cumulative mass release plot is then taken against the square root of
time (figure 15). This ensures the data is in the proper format to apply equation (4) from
the mathematical model. Taking the slope for the short times from this plot satisfies
equation (11) from chapter 4. With this slope, the diffusion coefficient can be solved.
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Figure 15. (A) The cumulative percent of dexamethasone 21-phosphate released per fiber into
PBS versus time. (B) The cumulative percent of dexamethasone 21-phosphate released per fiber
into PBS versus the square root of time. Dashed line indicates the slope for short times.

The standard deviation is substantially smaller than for the dexamethasone in PBS
case. This is most likely due to the solubility of dexamethasone 21-phosphate in PBS.
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During the first 45 minutes release of dexamethasone 21-phosphate with respect to the
square root of time was fairly linear. Approximately 60% of the drug was released in the
first 15 minutes; by 45 minutes nearly 95% had been released. Using the slope the
diffusion coefficient was estimated to be D = 2.36 x 10-13 m2/s. Refer to appendix
(Program Diffusion Coefficient for Dexamethasone 21-phosphate Calculations, page 85).
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Chapter 7
Dexamethasone 21-phosphate Loaded PLGA Coated Fiber Results

For this 3rd case dexamethasone 21-phosphate was diffusing through a PLGA
membrane into PBS. Since the same agent was being analyzed using the CZE machine,
as in chapter 5, the same standard curve was used (refer to figure 11). The
dexamethasone 21-phosphate loaded PLGA coated fibers were again placed in a PBS
solution and analyzed at various time periods (1, 2, 5, 8, 12, 17, 23, 30, 37, 44, 51, 58, 65,
72, 79, 86, 93, 100, and 107 days). After each incubation period the eluant was removed
and analyzed using CZE and then replaced with fresh PBS. This provided an accurate
method for determining the dexamethasone 21-phosphate content, which was eluted into
the PBS solution during each period (figure 16).

36

400

350

300

Area Units

250

200

150

100

50

0

0

10

20

30

40

50

60

70

80

90

100

110

Tim e (days )

Figure 16. CZE data obtained for each incubation period.

To use the mathematical model described in chapter 4 it is necessary to calculate
the concentration and the cumulative concentration levels at each time period. This can
be achieved as in the previous chapters using the standard curve (figure 11). Forming a
relationship between the two sets of data provides a direct correlation between time and
concentration levels. The peak areas for each sample were converted to their equivalent
concentration using this relationship (figure 17). The outlying bars in the figures
represent standard deviation for the data sets.
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Figure 17. Concentration eluted at each time interval for the dexamethasone 21-phosphate loaded PLGA
coated fibers.

Taking the corresponding concentration at each time interval and adding the
following concentration a cumulative relationship was formed. This shows the
cumulative release of dexamethasone 21-phosphate concentration for each time until
depletion from the coated fiber (figure 18). Refer to appendix (Program PLGA DEX21 –
Concentrations, page 68) for calculations.
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Figure 18. Cumulative concentration release against time for PLGA coated fibers.

On average the fibers were loaded with a concentration of 0.222 mg/ml of
dexamethasone 21-phosphate as verified by CZE having an equivalent mass of 44.4 μg
per fiber segment. Knowing the initial concentration allows the previous figure to be
converted to a cumulative mass release versus time plot (figure 19). This set of data is not
necessary in the calculation of the diffusion coefficient; however, this plot helps provides
a better understanding of the diffusion process. By day 17, approximately 52% of the
drug was released from the fiber through the PLGA membrane. Release was measured till
day 107 at which time ~98% of the agent had been released. Due to the increasing rate of
release in the later time intervals it is safe to assume that the fibers were very near to
complete elution by 107 days. This can be verified below by the diffusion rate trends.
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Figure 19. The cumulative percentage of dexamethasone 21-phosphate released from the PLGA membrane
surrounding the fiber into PBS versus time.

Using the concentration and cumulative concentration data with chapter 4’s
equation (12) individual time interval diffusion coefficients can be calculated. Refer to
the program (Program Diffusion through PLGA membrane Program, page 86) in the
appendix. Plotting these coefficients illustrates how diffusion is varying with respect to
time (figure 20).
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Figure 20. Diffusion rates at each time interval for dexamethasone 21-phosphate through a PLGA
membrane.

Analyzing (figure 20), it is evident that for a sustained period dexamethasone 21phoshate is diffusing through the PLGA membrane at an almost steady rate. From day 5
until day 58 it appears that nearly steady-state diffusion occurred. This model was
linearized and the steady-state diffusion coefficient for dexamethasone 21-phosphate
through a PLGA membrane was estimated to be D = 4.59 x 10-14 m2/s, a value not
previously reported. For the first two days the diffusion rate was faster because there is an
initial burst of release for the dexamethasone 21-phosphate. This is mainly due to the
residual drug left on the outside of the fiber. After 58 days the fiber’s coating began to
degrade releasing the agent at an increasing rate as time progressed. These two results
seem quite accurate and follow what was expected for release from the polymer, PLGA.
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Chapter 8
Discussion
8.1 Dexamethasone

The dried NDGA collagen fibers weigh on average 0.169 mg/fiber, have a
diameter of ~0.08 mm, and a length of 10 mm. When placed in a dexamethasone solution
overnight the fibers swell and absorb the drug. The hydrated fiber’s diameter increases to
0.117 mm on average. After 2 days nearly all of the dexamethasone was released into the
PBS solution, an estimated 0.021 mg/ml of dexamethasone (figure 9). The diffusion
coefficient of dexamethasone in the NDGA collagen fibers was found to be D = 1.86 x
10-14 m2/s, a value that has not been previously reported. The diffusion coefficient of
dexamethasone in the NDGA collagen fiber was compared to the diffusion coefficient for
dexamethasone in other media from the literature. The diffusion coefficient of
dexamethasone in the NDGA collagen fiber is less than that in cellulose acetate but
greater than in the poly(ether urethane), Tecoplast (Table 2).
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Table 2. Diffusion coefficients of dexamethasone in various media.
Medium

D [m2/s]

Reference

Water

6.82x10-10

Stokes-Einstein equation

Subcutaneous tissue

16
4.11±1.77 x10-10 Moussy et al. 2006

Subcutaneous tissue

17
4.01±2.01 x10-10 Moussy et al. 2006

Brain

2.0x10-10

Saltzman and Radomsky, 1991 18

Cellulose acetate membrane 3.15x10-11a

Barry and Brace, 1977 2

NDGA collagen fibers

1.86 x 10-14

This study.

Tecoplast

7.0 x 10-17

Lyu et al., 2005 14

PTMC

2.26 x 10-21b

Zhang et al., 2006 21

mPEG3-PTMC11

4.8 x 10-22c

Zhang et al., 2006 21

Tecothane75D

3.0 x 10-23

Lyu et al., 2005 14

a

Interpolated for 37°C

b

poly(trimethylene carbonate)

c

monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate)

8.2 Dexamethasone 21-phosphate

The dexamethasone 21-phosphate loaded NDGA collagen fibers were of the same
dimensions as the dexamethasone loaded fibers when hydrated. The primary difference
between these two agents is their capability for loading and their solubility. Protonated
free amines in the collagen phase bind with the negatively charged phosphate groups in
the dexamethasone 21-phosphate. This binding process enables the fibers to be loaded
with an estimated 0.222 mg/ml of drug when loaded in a 3% acetic acid solution. This is
43

nearly 11 times greater than when the fibers are loaded with dexamethasone in ethanol.
The two agents are loaded using different solvents (ethanol versus 3% acetic acid). In
water dexamethasone is nearly insoluble having a solubility of 10 mg/100 ml. However,
it is highly soluble in ethanol3. On the other hand, dexamethasone 21-phosphate is watersoluble. However, dexamethasone 21-phosphate is loaded in the 3% acetic acid (v/v, in
water) because it alters the pH levels causing the collagen phase to become positively
charged favoring ionic interaction with the negatively charged phosphate groups
increasing the loading potential. When examining the data for dexamethasone 21phosphate elution, it is evident that the release rate is much faster than for
dexamethasone. After 75 minutes the dexamethasone 21-phosphate had left the fiber.
This rapid elution is due to the solubility of this drug in PBS and the neutralization of the
collagen in PBS.
The diffusion coefficient of dexamethasone 21-phosphate in the NDGA collagen
fibers was found to be D = 2.36 x 10-13 m2/s, a value that has not previously been
reported. The diffusion coefficient for dexamethasone 21-phosphate in the NDGA
collagen fiber is approximately 12 times greater than for dexamethasone in the NDGA
collagen fiber.

8.3 PLGA Coated Dexamethasone 21-phosphate Loaded Fibers

Clearly, dexamethasone 21-phosphate shows a greater capacity for loading in the
NDGA collagen fibers. However, since this agent is water-soluble the release rate is too
rapid and does not demonstrate substantial benefit for drug delivery applications. To use
this anti-inflammatory drug the release rate must be controlled in a sustained manner,
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which is why a PLGA membrane was applied to the fibers. This membrane increased the
fibers average diameter to 0.306 mm (n=30). The preliminary results for the 3rd case
show that after 100 days the coated fibers continue to release dexamethasone 21phosphate (figure 18). The PLGA membrane also sustains a nearly steady state rate of
release for the first 58 days. This steady state diffusion coefficient was estimated to be D
= 4.59 x 10-14 m2/s, a value not previously reported. This rate is approximately 5 times
slower than that of the uncoated fiber loaded with dexamethasone 21-phosphate. The rate
is based off of the diffusional distance, which corresponds to the thickness of the fibers
coating. These preliminary results illustrate the potential that PLGA coated NDGA
collagen fibers possess for a drug delivery system.
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Chapter 9
Conclusion
9.1 Summary

It is evident that there is a substantial need for a method to continuously monitor
blood glucose levels via an implantable sensor. Applying an effective drug delivery
system for anti-inflammatory and immunosuppresant agents in vivo will increase the
biosensors acceptance by the host, increase functionality and lifespan20. This paper has
shown that NDGA collagen fibers can be loaded with a therapeutic agent and release of
this agent can be determined and controlled. The loading process is principally a
mechanical process. Therefore, loading the fibers with other agents (or combinations of
agents) should be a viable option. By altering the fiber length or thickness during
fabrication potential loading volumes can be increased and by utilizing different
chemistries drug retention in the fibers can be improved. If further control of release is
required different biopolymer membranes could be applied. Similar to the fibers, the
thickness of the coatings can be adjusted to promote the optimum rate of diffusion.
Previous studies have demonstrated that the NDGA collagen fibers are biocompatible in
vitro and in vivo12. Thus, NDGA collagen fibers exhibit a great deal of potential for in
vivo applications and clearly represent a novel drug delivery system.
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9.2 Future Works

Now that an effective system has been proposed to deliver anti-inflammatory
agents, the next step will be to incorporate these fibers into the implantable glucose
sensor. The next proposed project would be to apply these fibers to glucose sensors,
which our lab has developed, and implant these for in vivo testing. This will hopefully
provide insight into how effective the dexamethasone 21-phosphate is at reducing
inflammation and fibrosis around the implanted sensor and show if the sensitivity and
lifespan of the sensor is improved. If the results from this experiment show promise, drug
loading amounts and diffusion rates may be adjusted during fabrication to model the most
efficient system for use with the sensor. Further studies may include the loading of
different agents into the fibers, such as Vascular Endothelial Growth Factor (VEGF).
VEGF should increase blood vessel growth; thus, has potential for increasing sensitivity
in the sensor.
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Appendices
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Appendix A: Additional Information and Figures

Diffusion
•

Diffusion is a passive transport process in which the driving potential is the
species concentration gradient.

•

The higher concentration will permeate through the fiber to the lower
concentration until a balance is achieved.

Figure 21. This figure illustrates the process at which the agents are diffusing from the fibers.
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Appendix A: (Continued)

NDGA
collagen
fiber

PLGA
coating

Figure 22. Cross-section of PLGA coated fiber.

52

Appendix A: (Continued)

Detailed Fiber Fabrication Protocol
The fiber fabrication process is a very delicate and intricate procedure. It is
essential to follow the required steps to produce high strength, biocompatible fibers. The
entire process takes four days and can be broken up into daily procedures. The following
is a more detailed account of the fabrication procedure.
The first day covers initial setup and collagen production. To begin attach
0.32ml/cm hydrated dialysis tubing to the end of a 5 ml Ependorf Repeater pipet tips. It is
essential not to crimp or hit the dialysis tubing on any sharp edges, as it is very fragile
and important to the collagen formation process. Use a piece of silicon tubing to hold the
41.5cm length dialysis tubing onto the repeater tip. The collagen solution used is 0.13%
w/v in 3% acetic acid. This 0.13% w/v yields the strongest fibers feasible, with around a
250 Newton tensile strength. Load the collagen solution into the dialysis tubing. Make
sure to seal the end of the tubing, so as not to lose the solution. Aspirate any air bubbles,
as this will weaken the collagen fibril formation. Make sure the tubing assemblies are
hung in tension to prevent imperfections in fibril alignment and place them in a 4-liter
graduated cylinder of de-ionized water. Change the water every 30 minutes for at least 7
hours. This washing step is necessary as it dialyses the acetic acid from the collagen
solution. Any remaining acetic acid left in the tubing will breakdown the collagen
preventing fibril alignment and formation. Once the washing is complete transfer the
tubing assemblies into 4-liters of freshly made PBS, pH 7.4. Place this into a 37°C
incubator overnight.
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Appendix A: (Continued)

The second day encompasses drying the fibers. After 16 hours of incubation
remove the PBS filled graduated cylinder. During this time period the collagen will have
re-natured and formed fibrils. Once again, transfer the tubing assembly into a 4-liter
graduated cylinder filled with de-ionized water for 30 minutes to remove any salt that
was absorbed during incubation. Transfer the fibers to a flat pan filled with 1cm of deionized water. At this stage in fabrication the fibers are extremely fragile. Ensure the
fibers will not twist or kink, as this will promote weaknesses in the drying phase. The
drying device is essentially a motor drive the lifts a jack at variable speeds. Attached to
the jack is a Styrofoam block that overhangs the pan. Attach the fiber ends to a bamboo
toothpick by overlapping them. Place the toothpick approximately 4cm out of the water
into the Styrofoam block. Allow the fibers to dry here for about 2 hours, until their
diameter is about 1mm. Once the fiber is dry the strength will increase dramatically.
Running the lifting device at rate of 1.4mm/min ensures exposed fibers will dry and
strengthen enough to support the hydrated fibers that are being lifted from the pan.
On the third day NDGA cross-linking takes place. Remove the dried fibers from
the lifting device and use sewing thread to bunch the fibers together at one end. Making
sure the fibers remain aligned and in slight tension using the thread. Place the fibers into
a long glass tube with stoppers at each end. Create a 27ml solution of 0.1 M sodium
phosphate buffer increase the pH level to 9.0 using NaOH. Sparge this solution for two
minutes. While the buffer is sparging, dissolve 90mg of NDGA in 0.4 M NaOH. Mix
both of these solutions together and place contents inside the glass tube that houses the
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fibers. Set glass tube on a rocker overnight. This step will help the fibers to cross-link
evenly with the NDGA.
The final day is used to wash the fibers and dry them. Begin by removing the
NDGA solution and briefly wash the fibers with 5ml of 70% ethanol. Empty contents of
the glass tube and then fill 2/3 of tube with ethanol again. Seal the tube and replace it
back onto the rocker for about 20 minutes. Drain again and perform final wash refilling
tube with ethanol and placing on rocker for 60 minutes. Finally, drain the tube and
remove fibers carefully. Hang vertically for drying. Ensure the fibers are separated while
drying and in tension. Allow fibers to dry overnight.
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Figure 23. Fabrication procedure. Top panel: 1) Take 0.13%(w/v) collagen in 3% acetic acid and place in
dialysis tubing. 2) Dialyze in de-ionized H2O for ~7 hrs. 3) Incubate at 37 °C for 16 hrs in 4L of PBS
solution 4) Dialyze in de-ionized H2O again. 5) Extrude and dry fibers; NDGA Cross-linking. Middle
panel: 6) Place the dry fibers into a glass tube with NDGA/sodium phosphate buffer solution. 7) Cap tube
and place on rocker overnight. 8) Wash fibers in 70% EtOH to remove unbound NDGA. 9) Remove
NDGA treated fibers and hang to dry. 10) NDGA cross-linked collagen fibers; Drug Loading and Elution.
Bottom panel: 11) Dexamethasone loaded in 70% EtOH solution or dexamethasone 21-phosphate loaded in
3% acetic acid overnight. 12) Discard solution and dry fibers for one day. 13) Place drug loaded fibers in
PBS solution and use Capillary Zone Electrophoresis to measure drug elution at specified time intervals.
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> restart;
Program Dexamethasone - Concentrations
This program calculates first the concentrations at corresponding times (a), then the
cumulative concentrations (b) including standard deviations.
This equation was obtained from the standard curve of DEX in PBS calculated by Tian
Davis' experiments. Using data provided by her June 5th, 2006 excel sheet. This formula
represents how much DEX is eluted (y in area units) depending on the concentration
loaded into the fibers (x in mg/ml).
y:=14501*x-33.932
This equation is then rewritten in terms of x:
> x:=(y+33.932)/14501;
y
x :=
+ 0.002339976553
14501

This equation was then used with corresponding data from Tian Davis' experiment 6 from
June 1st, 2006 email. In experiment 6 Tian found a relationship between the DEX eluted
in PBS to the time. Using the data from this experiment we shall formulate a relationship
between the concentration (mg/ml) vs. time (hours).
case 1: at time 0 there was no area units present.
> y:=0;

y := 0

> Concentration[time=0]:=evalf(x);
Concentration time = 0 := 0.002339976553
case 2: at time = 1 hr, 78.81 area units were eluted.
> y:=78.81;
Concentration[time=1]:=(y+33.932)/14501;
y := 78.81
Concentration time = 1 := 0.007774774153

case 3a: at time = 3 hr, 69.8 area units were eluted.
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> y:=69.8;
Concentration[time=3]:=(y+33.932)/14501;
y := 69.8
Concentration time = 3 := 0.007153437694

case 4a: at time = 6 hr, 49.34 area units were eluted.
> y:=49.34;
Concentration[time=6]:=(y+33.932)/14501;
>
y := 49.34
Concentration time = 6 := 0.005742500517

case 5a: at time = 9 hr, 33.81 area units were eluted.
> y:=33.81;
Concentration[time=9]:=(y+33.932)/14501;
y := 33.81
Concentration time = 9 := 0.004671539893

case 6a: at time = 12 hr, 12.91 area units were eluted.
> y:=12.91;
Concentration[time=12]:=(y+33.932)/14501;
y := 12.91
Concentration time = 12 := 0.003230259982

case 7a: at time = 24 hr, 10.74 area units were eluted.
> y:=10.74;
Concentration[time=24]:=(y+33.932)/14501;
y := 10.74
Concentration time = 24 := 0.003080615130

case8a: at time = 30 hr, 3.7 area units were eluted.
> y:=3.7;
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Concentration[time=30]:=(y+33.932)/14501;
y := 3.7
Concentration time = 30 := 0.002595131370

case9a: at time = 48 hr, 8.27 area units were eluted.
> y:=8.27;
Concentration[time=48]:=(y+33.932)/14501;
y := 8.27
Concentration time = 48 := 0.002910282049

These are the cumulative concentrations:
case 1: at time 0 there was no area units present.
case 2: at time = 1 hr, 78.81 area units were eluted.
> y:=78.81;
CumulativeConcentration[time=1]:=(y+33.932)/14501;
dev:=78.81+(7.485608414);
UpperStd[time=1]:=(dev+33.932)/14501;
DevDiff:=.8290987408e-2-.7774774153e-2;
y := 78.81
CumulativeConcentration

time = 1

:= 0.007774774153

dev := 86.29560841
UpperStd time = 1 := 0.008290987408

DevDiff := 0.000516213255
case 3b: at time = 3 hr, 69.8 more area units were eluted.
> y:=78.81+69.8;
CumulativeConcentration[time=3]:=(y+33.932)/14501;
dev:=148.61+(23.99038928);
UpperStd[time=3]:=(dev+33.932)/14501;
DevDiff:=.1424263080e-1-.1258823529e-1;
y := 148.61
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CumulativeConcentration

time = 3

:= 0.01258823529

dev := 172.6003893
UpperStd time = 3 := 0.01424263080

DevDiff := 0.00165439551
case 4b: at time = 6 hr, 49.34 more area units were eluted.
> y:=78.81+69.8+49.34;
CumulativeConcentration[time=6]:=(y+33.932)/14501;
dev:=197.95+(42.08267656);
UpperStd[time=6]:=(dev+33.932)/14501;
DevDiff:=.1889281267e-1-.1599075925e-1;

y := 197.95
CumulativeConcentration

time = 6

:= 0.01599075925

dev := 240.0326766
UpperStd time = 6 := 0.01889281267

DevDiff := 0.00290205342
case 5b: at time = 9 hr, 33.81 more area units were eluted.
> y:=78.81+69.8+49.34+33.81;
CumulativeConcentration[time=9]:=(y+33.932)/14501;
dev:=231.76+(64.53328512);
UpperStd[time=9]:=(dev+33.932)/14501;
DevDiff:=.2277258707e-1-.1832232260e-1;

y := 231.76
CumulativeConcentration

time = 9

:= 0.01832232260

dev := 296.2932851
UpperStd time = 9 := 0.02277258707

DevDiff := 0.00445026447
case 6b: at time = 12 hr, 12.91 more area units were eluted.
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> y:=78.81+69.8+49.34+33.81+12.91;
CumulativeConcentration[time=12]:=(y+33.932)/14501;
dev:=244.67+(71.77189252);
UpperStd[time=12]:=(dev+33.932)/14501;
DevDiff:=.2416205037e-1-.1921260602e-1;

y := 244.67
CumulativeConcentration

time = 12

:= 0.01921260602

dev := 316.4418925
UpperStd time = 12 := 0.02416205037

DevDiff := 0.00494944435
case 7b: at time = 24 hr, 10.74 more area units were eluted.
> y:=78.81+69.8+49.34+33.81+12.91+10.74;
CumulativeConcentration[time=24]:=(y+33.932)/14501;
dev:=255.41+(82.22359015);
UpperStd[time=24]:=(dev+33.932)/14501;
DevDiff:=.2562344598e-1-.1995324460e-1;

y := 255.41
CumulativeConcentration

time = 24

:= 0.01995324460

dev := 337.6335902
UpperStd time = 24 := 0.02562344598

DevDiff := 0.00567020138
case 8b: at time = 30 hr, 3.7 more area units were eluted.
> y:=78.81+69.8+49.34+33.81+12.91+10.74+3.7;
CumulativeConcentration[time=30]:=(y+33.932)/14501;
dev:=259.11+(82.27916504);
UpperStd[time=30]:=(dev+33.932)/14501;
DevDiff:=.2588243328e-1-.2020839942e-1;
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y := 259.11
CumulativeConcentration

time = 30

:= 0.02020839942

dev := 341.3891650
UpperStd time = 30 := 0.02588243328

DevDiff := 0.00567403386
case 9b: at time = 48 hr, 8.27 more area units were eluted.
> y:=78.81+69.8+49.34+33.81+12.91+10.74+3.7+8.27;
CumulativeConcentration[time=48]:=(y+33.932)/14501;
dev:=267.38+(77.96223872);
UpperStd[time=48]:=(dev+33.932)/14501;
DevDiff:=.2615504025e-1-.2077870491e-1;

y := 267.38
CumulativeConcentration

time = 48

:= 0.02077870491

dev := 345.3422387
UpperStd time = 48 := 0.02615504025

DevDiff := 0.00537633534
An average of 267.38 area units eluted which is equivalent to a total of 0.02077870491
mg/ml
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> restart;
Program Dexamethasone 21-phosphate Concentrations
This program calculates first the concentrations at corresponding times (a), then the
cumulative concentrations (b) and standard deviations.
This equation was obtained from the standard curve of dexamethasone 21-phosphate
(DEX21) in PBS calculated by Tian Davis' experiments. Using data provided by her June
13, 2006 excel sheet called 'Exp 15 std'. This formula represents how much DEX21 is
eluted (y in area units) depending on the concentration loaded into the fibers (x in mg/ml).
y:=13571*x-328.71
This equation is then rewritten in terms of x:
> x:=(y+328.71)/13571;
y
x :=
+ 0.02422150173
13571

This equation was then used with corresponding data from Tian Davis' experiment 8 from
July 7th, 2006 email. In experiment 8 Tian found a relationship between the DEX21
eluted in PBS to the time. Using the data from this experiment we shall formulate a
relationship between the concentration (mg/ml) vs. time (minutes).
case 1: at time 0 there was no area units present.
> y:=0;

y := 0

> Concentration[time=0]:=evalf(x);
Concentration time = 0 := 0.02422150173
case 2: at time = 15 minutes, 1498.27 area units were eluted.
> y:=1498.27;
Concentration[time=15]:=(y+328.71)/13571;
y := 1498.27
Concentration time = 15 := 0.1346238302

case 3a: at time = 30 minutes, 727.55 area units were eluted.
> y:=727.55;
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Concentration[time=30]:=(y+328.71)/13571;

y := 727.55
Concentration time = 30 := 0.07783214207

case 4a: at time = 45 minutes, 317.15 area units were eluted.
> y:=317.15;
Concentration[time=45]:=(y+328.71)/13571;
>
y := 317.15
Concentration time = 45 := 0.04759118709

case 5a: at time = 60 minutes, 106.52 area units were eluted.
> y:=106.52;
Concentration[time=60]:=(y+328.71)/13571;

y := 106.52
Concentration time = 60 := 0.03207059170

case 6a: at time = 75 minutes, 35.5 area units were eluted.
> y:=35.5;
Concentration[time=75]:=(y+328.71)/13571;

y := 35.5
Concentration time = 75 := 0.02683737381

Here, case 2 is redone because the standard deviation was needed.
case 2: at time = 15 minutes, 1498.27 area units were eluted.
> y:=1498.27;
Concentration[time=15]:=(y+328.71)/13571;
dev:=1498.27+142.4087626;
UpperStd[time=15]:=(dev+328.71)/13571;
devDiff:=.1451174388-.1346238302;
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y := 1498.27
Concentration time = 15 := 0.1346238302

dev := 1640.678763
UpperStd time = 15 := 0.1451174388

devDiff := 0.0104936086
These are the cumulative concentrations (b) and also the standard deviations for the data.
Notice case 1 and 2 were omitted because they are the same.
case 3b: at time = 30 minutes, 727.55 more area units were eluted.
> y:=1498.27+727.55;
CumulativeConcentration[time=30]:=(y+328.71)/13571;
dev:=2225.82+151.9352698;
UpperStd[time=30]:=(dev+328.71)/13571;
devDiff:=.1994300545-.1882344705;

y := 2225.82
CumulativeConcentration

time = 30

:= 0.1882344705

dev := 2377.755270
UpperStd time = 30 := 0.1994300545

devDiff := 0.0111955840
case 4b: at time = 45 minutes, 317.15 more area units were eluted.
> y:=1498.27+727.55+317.15;
CumulativeConcentration[time=45]:=(y+328.71)/13571;
dev:=2542.97+159.5902465;
UpperStd[time=45]:=(dev+328.71)/13571;
devDiff:=.2233638085-.2116041559;
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y := 2542.97
CumulativeConcentration

time = 45

:= 0.2116041559

dev := 2702.560246
UpperStd time = 45 := 0.2233638085

devDiff := 0.0117596526
case 5b: at time = 60 minutes, 106.52 more area units were eluted.
> y:=1498.27+727.55+317.15+106.52;
CumulativeConcentration[time=60]:=(y+328.71)/13571;
dev:=2649.49+168.421221;
UpperStd[time=60]:=(dev+328.71)/13571;
devDiff:=.2318636225-.2194532459;

y := 2649.49
CumulativeConcentration

time = 60

:= 0.2194532459

dev := 2817.911221
UpperStd time = 60 := 0.2318636225

devDiff := 0.0124103766
case 6b: at time = 75 minutes, 35.5 more area units were eluted.
> y:=1498.27+727.55+317.15+106.52+35.5;
CumulativeConcentration[time=75]:=(y+328.71)/13571;
dev:=2684.99+171.8312121;
UpperStd[time=75]:=(dev+328.71)/13571;
devDiff:=.2347307650-.2220691179;

y := 2684.99
CumulativeConcentration

time = 75

:= 0.2220691179

dev := 2856.821212
UpperStd time = 75 := 0.2347307650

devDiff := 0.0126616471
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An average of 2684.99 area units were eluted which is equivalent to a total of
0.2220691179 mg/ml
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> restart;
Program PLGA DEX21 - Concentrations
This program calculates the concentrations at corresponding times (a), and the
cumulative concentrations at corresponding times (b). Both include standard deviation
calculations.
This equation was obtained from the standard curve of DEX21 in PBS calculated by Tian
Davis' experiments. Using data provided by her June 13, 2006 excel sheet called 'Exp 15
std'. This formula represents how much DEX21 is eluted (y in area units) depending on
the concentration level (x in mg/ml).
y:=13571*x-328.71
This equation is then rewritten in terms of x:
> x:=(y+328.71)/13571;
y
x :=
+ 0.02422150173
13571

This equation was then used with corresponding data from Tian Davis' experiment 14. In
experiment 14 Tian found a relationship between the DEX21 eluted from the PLGA
coated fibers into PBS with respect to time. Using the data from this experiment we shall
formulate a relationship between the concentration (mg/ml) vs. time (days).
case 1: at time 0 there was no area units present.
case 2: at time = 1 day, 371.2 area units were eluted.
> y:=371.2;
Concentration[time=1]:=(y+328.71)/13571;
dev:=254.0424943+371.2;
UpperStd[time=1]:=(dev+328.71)/13571;
devDiff:=.7029345621e-1-.5157394444e-1;

y := 371.2
Concentration time = 1 := 0.05157394444

dev := 625.2424943
UpperStd time = 1 := 0.07029345621

devDiff := 0.01871951177
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case 3a: at time = 2 days, 136.33333 area units were eluted.
> y:=136.333333;
Concentration[time=2]:=(y+328.71)/13571;
dev:=91.40963966+136.333333;
UpperStd[time=2]:=(dev+328.71)/13571;
devDiff:=.4100309282e-1-.3426743298e-1;

y := 136.333333
Concentration time = 2 := 0.03426743298

dev := 227.7429727
UpperStd time = 2 := 0.04100309282

devDiff := 0.00673565984
case 4a: at time = 5 days, 221.93333 area units were eluted.
> y:=221.9333333;
Concentration[time=5]:=(y+328.71)/13571;
dev:= 124.4473115+y;
UpperStd[time=5]:=(dev+328.71)/13571;
devDiff:=.4974509209e-1-.4057500061e-1;

y := 221.9333333
Concentration time = 5 := 0.04057500061

dev := 346.3806448
UpperStd time = 5 := 0.04974509209

devDiff := 0.00917009148
case 5a: at time = 8days, 146.66667 area units were eluted.
> y:=146.6666667;
Concentration[time=8]:=(y+328.71)/13571;
dev:= 59.99907407+y;
UpperStd[time=8]:=(dev+328.71)/13571;
devDiff:=.3944998458e-1-.3502886056e-1;
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y := 146.6666667
Concentration time = 8 := 0.03502886056

dev := 206.6657408
UpperStd time = 8 := 0.03944998458

devDiff := 0.00442112402
case 6a: at time = 12days, 175.266667 area units were eluted.
> y:=175.2666667;
Concentration[time=12]:=(y+328.71)/13571;
dev:= 85.8860356+y;
UpperStd[time=12]:=(dev+328.71)/13571;
devDiff:=.4346494011e-1-.3713629553e-1;

y := 175.2666667
Concentration time = 12 := 0.03713629553

dev := 261.1527023
UpperStd time = 12 := 0.04346494011

devDiff := 0.00632864458
case 7a: at time = 17days, 178.733333 area units were eluted.
> y:=178.7333333;
Concentration[time=17]:=(y+328.71)/13571;
dev:= 93.18154324+y;
UpperStd[time=17]:=(dev+328.71)/13571;
devDiff:=.4425796747e-1-.3739174219e-1;

y := 178.7333333
Concentration time = 17 := 0.03739174219

dev := 271.9148765
UpperStd time = 17 := 0.04425796747

devDiff := 0.00686622528
case 8a: at time = 23days, 199.333333 area units were eluted.
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> y:=199.3333333;
Concentration[time=23]:=(y+328.71)/13571;
dev:= 81.15999288+y;
UpperStd[time=23]:=(dev+328.71)/13571;
devDiff:=.4489008372e-1-.3890968486e-1;

y := 199.3333333
Concentration time = 23 := 0.03890968486

dev := 280.4933262
UpperStd time = 23 := 0.04489008372

devDiff := 0.00598039886
case 9a: at time = 30days, 210.8 area units were eluted.
> y:=210.8;
Concentration[time=30]:=(y+328.71)/13571;
dev:= 74.98762861+y;
UpperStd[time=30]:=(dev+328.71)/13571;
devDiff:=.4528020253e-1-.3975462383e-1;

y := 210.8
Concentration time = 30 := 0.03975462383

dev := 285.7876286
UpperStd time = 30 := 0.04528020253

devDiff := 0.00552557870
case 10a: at time = 37days, 141.266667 area units were eluted.
> y:=141.2666667;
Concentration[time=37]:=(y+328.71)/13571;
dev:= 47.21487525+y;
UpperStd[time=37]:=(dev+328.71)/13571;
devDiff:=.3811005394e-1-.3463095326e-1;
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y := 141.2666667
Concentration time = 37 := 0.03463095326

dev := 188.4815420
UpperStd time = 37 := 0.03811005394

devDiff := 0.00347910068
case 11a: at time = 44days, 108.133333 area units were eluted.
> y:=108.1333333;
Concentration[time=44]:=(y+328.71)/13571;
dev:= 44.58985934+y;
UpperStd[time=44]:=(dev+328.71)/13571;
devDiff:=.3547514498e-1-.3218947265e-1;

y := 108.1333333
Concentration time = 44 := 0.03218947265

dev := 152.7231926
UpperStd time = 44 := 0.03547514498

devDiff := 0.00328567233
case 12a: at time = 51days, 91.8 area units were eluted.
> y:=91.8;
Concentration[time=51]:=(y+328.71)/13571;
dev:= 53.45226323+y;
UpperStd[time=51]:=(dev+328.71)/13571;
devDiff:=.3492463806e-1-.3098592587e-1;

y := 91.8
Concentration time = 51 := 0.03098592587

dev := 145.2522632
UpperStd time = 51 := 0.03492463806

devDiff := 0.00393871219
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case 13a: at time = 58days, 76.933333 area units were eluted.
> y:=76.93333333;
Concentration[time=58]:=(y+328.71)/13571;
dev:= 57.3349806+y;
UpperStd[time=58]:=(dev+328.71)/13571;
devDiff:=.3411526887e-1-.2989045268e-1;

y := 76.93333333
Concentration time = 58 := 0.02989045268

dev := 134.2683139
UpperStd time = 58 := 0.03411526887

devDiff := 0.00422481619
case 14a: at time = 65days, 129.466667 area units were eluted.
> y:=129.4666667;
Concentration[time=65]:=(y+328.71)/13571;
dev:= 102.1144782+y;
UpperStd[time=65]:=(dev+328.71)/13571;
devDiff:=.4128591444e-1-.3376145212e-1;

y := 129.4666667
Concentration time = 65 := 0.03376145212

dev := 231.5811449
UpperStd time = 65 := 0.04128591444

devDiff := 0.00752446232
case 15a: at time = 72days, 133.66667 area units were eluted.
> y:=133.6666667;
Concentration[time=72]:=(y+328.71)/13571;
dev:= 69.89714666+y;
UpperStd[time=72]:=(dev+328.71)/13571;
devDiff:=.3922141429e-1-.3407093557e-1;
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y := 133.6666667
Concentration time = 72 := 0.03407093557

dev := 203.5638134
UpperStd time = 72 := 0.03922141429

devDiff := 0.00515047872
case 16a: at time = 79days, 107.4666667 area units were eluted.
> y:=107.4666667;
Concentration[time=79]:=(y+328.71)/13571;
dev:= 43.57279987+y;
UpperStd[time=79]:=(dev+328.71)/13571;
devDiff:=.3535107705e-1-.3214034829e-1;

y := 107.4666667
Concentration time = 79 := 0.03214034829

dev := 151.0394666
UpperStd time = 79 := 0.03535107705

devDiff := 0.00321072876
case 17a: at time = 86days, 76.7333333 area units were eluted.
> y:=76.73333333;
Concentration[time=86]:=(y+328.71)/13571;
dev:= 47.03568385+y;
UpperStd[time=86]:=(dev+328.71)/13571;
devDiff:=.3334161205e-1-.2987571537e-1;

y := 76.73333333
Concentration time = 86 := 0.02987571537

dev := 123.7690172
UpperStd time = 86 := 0.03334161205

devDiff := 0.00346589668
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case 18a: at time = 93days, 57.0666667 area units were eluted.
> y:=57.06666667;
Concentration[time=93]:=(y+328.71)/13571;
dev:= 39.87368946+y;
UpperStd[time=93]:=(dev+328.71)/13571;
devDiff:=.3136470091e-1-.2842654680e-1;

y := 57.06666667
Concentration time = 93 := 0.02842654680

dev := 96.94035613
UpperStd time = 93 := 0.03136470091

devDiff := 0.00293815411
case 19a: at time = 100days, 35.5333333 area units were eluted.
> y:=35.53333333;
Concentration[time=100]:=(y+328.71)/13571;
dev:= 28.39268294+y;
UpperStd[time=100]:=(dev+328.71)/13571;
devDiff:=.2893198852e-1-.2683983003e-1;

y := 35.53333333
Concentration time = 100 := 0.02683983003

dev := 63.92601627
UpperStd time = 100 := 0.02893198852

devDiff := 0.00209215849
case 20a: at time = 107days, 30.8666667 area units were eluted.
> y:=30.86666667;
Concentration[time=107]:=(y+328.71)/13571;
dev:= 38.54694108+y;
UpperStd[time=107]:=(dev+328.71)/13571;
devDiff:=.2933635014e-1-.2649595952e-1;
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y := 30.86666667
Concentration time = 107 := 0.02649595952

dev := 69.41360775
UpperStd time = 107 := 0.02933635014

devDiff := 0.00284039062
These are the cumulative concentrations at corresponding times (b) with standard
deviations.
Note that case 1 and 2 are omitted because they were already solved in part (a).
case 3b: at time = 2 days, 136.3333 more area units were eluted.
> y:=507.5333333;
CumulativeConcentration[time=2]:=(y+328.71)/13571;
dev:=507.5333333+298.679929;
UpperStd[time=2]:=(dev+328.71)/13571;
devDiff:=.8362856549e-1-.6161987571e-1;

y := 507.5333333
CumulativeConcentration

time = 2

:= 0.06161987571

dev := 806.2132623
UpperStd time = 2 := 0.08362856549

devDiff := 0.02200868978
case 4b: at time = 5 days, 221.9333 more area units were eluted.
> y:=729.4666667;
CumulativeConcentration[time=5]:=(y+328.71)/13571;
dev:=729.4666667+357.1519751;
UpperStd[time=5]:=(dev+328.71)/13571;
devDiff:=.1042906670-.7797337460e-1;
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y := 729.4666667
CumulativeConcentration

time = 5

:= 0.07797337460

dev := 1086.618642
UpperStd time = 5 := 0.1042906670

devDiff := 0.02631729240
case 5b: at time = 8 days, 146.6667 more area units were eluted.
> y:=876.1333333;
CumulativeConcentration[time=8]:=(y+328.71)/13571;
dev:=876.1333333+396.7563344;
UpperStd[time=8]:=(dev+328.71)/13571;
devDiff:=.1180163340-.8878073342e-1;

y := 876.1333333
CumulativeConcentration

time = 8

:= 0.08878073342

dev := 1272.889668
UpperStd time = 8 := 0.1180163340

devDiff := 0.02923560058
case 6b: at time = 12 days, 175.2667 more area units were eluted.
> y:=1051.4;
CumulativeConcentration[time=12]:=(y+328.71)/13571;
dev:=1051.4+443.6188554;
UpperStd[time=12]:=(dev+328.71)/13571;
devDiff:=.1343842646-.1016955272;

y := 1051.4
CumulativeConcentration

time = 12

:= 0.1016955272

dev := 1495.018855
UpperStd time = 12 := 0.1343842646

devDiff := 0.0326887374
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case 7b: at time = 17 days, 178.73333 more area units were eluted.
> y:=1230.133333;
CumulativeConcentration[time=17]:=(y+328.71)/13571;
dev:=1230.133333+513.1005749;
UpperStd[time=17]:=(dev+328.71)/13571;
devDiff:=.1526743724-.1148657677;

y := 1230.133333
CumulativeConcentration

time = 17

:= 0.1148657677

dev := 1743.233908
UpperStd time = 17 := 0.1526743724

devDiff := 0.0378086047
case 8b: at time = 23 days, 199.3333 more area units were eluted.
> y:=1429.466667;
CumulativeConcentration[time=23]:=(y+328.71)/13571;
dev:=1429.466667+562.1573327;
UpperStd[time=23]:=(dev+328.71)/13571;
devDiff:=.1709773782-.1295539508;

y := 1429.466667
CumulativeConcentration

time = 23

:= 0.1295539508

dev := 1991.624000
UpperStd time = 23 := 0.1709773782

devDiff := 0.0414234274
case 9b: at time = 30 days, 210.8 more area units were eluted.
> y:=1640.266667;
CumulativeConcentration[time=30]:=(y+328.71)/13571;
dev:=1640.266667+619.3419178;
UpperStd[time=30]:=(dev+328.71)/13571;
devDiff:=.1907242344-.1450870729;
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y := 1640.266667
CumulativeConcentration

time = 30

:= 0.1450870729

dev := 2259.608585
UpperStd time = 30 := 0.1907242344

devDiff := 0.0456371615
case 10b: at time = 37 days, 141.2667 more area units were eluted.
> y:=1781.533333;
CumulativeConcentration[time=37]:=(y+328.71)/13571;
dev:=1781.533333+610.5314898;
UpperStd[time=37]:=(dev+328.71)/13571;
devDiff:=.2004844759-.1554965244;
y := 1781.533333
CumulativeConcentration

time = 37

:= 0.1554965244

dev := 2392.064823
UpperStd time = 37 := 0.2004844759

devDiff := 0.0449879515
case 11b: at time = 44 days, 108.1333 more area units were eluted.
> y:=1889.666667;
CumulativeConcentration[time=44]:=(y+328.71)/13571;
dev:=1889.666667+593.91928;
UpperStd[time=44]:=(dev+328.71)/13571;
devDiff:=.2072283506-.1634644954;

y := 1889.666667
CumulativeConcentration

time = 44

:= 0.1634644954

dev := 2483.585947
UpperStd time = 44 := 0.2072283506

devDiff := 0.0437638552
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case 12b: at time = 51 days, 91.8 more area units were eluted.
> y:=1981.466667;
CumulativeConcentration[time=51]:=(y+328.71)/13571;
dev:=1981.466667+558.2319112;
UpperStd[time=51]:=(dev+328.71)/13571;
devDiff:=.2113630961-.1702289195;

y := 1981.466667
CumulativeConcentration

time = 51

:= 0.1702289195

dev := 2539.698578
UpperStd time = 51 := 0.2113630961

devDiff := 0.0411341766
case 13b: at time = 58 days, 76.9333 more area units were eluted.
> y:=2058.4;
CumulativeConcentration[time=58]:=(y+328.71)/13571;
dev:=2058.4+521.9679322;
UpperStd[time=58]:=(dev+328.71)/13571;
devDiff:=.2143598800-.1758978704;

y := 2058.4
CumulativeConcentration

time = 58

:= 0.1758978704

dev := 2580.367932
UpperStd time = 58 := 0.2143598800

devDiff := 0.0384620096
case 14b: at time = 65 days, 129.4667 more area units were eluted.
> y:=2187.866667;
CumulativeConcentration[time=65]:=(y+328.71)/13571;
dev:=2187.866667+506.5052703;
UpperStd[time=65]:=(dev+328.71)/13571;
devDiff:=.2227604404-.1854378208;
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y := 2187.866667
CumulativeConcentration

time = 65

:= 0.1854378208

dev := 2694.371937
UpperStd time = 65 := 0.2227604404

devDiff := 0.0373226196
case 15b: at time = 72 days, 133.6667 more area units were eluted.
> y:=2321.533333;
CumulativeConcentration[time=72]:=(y+328.71)/13571;
dev:=2321.533333+481.014241;
UpperStd[time=72]:=(dev+328.71)/13571;
devDiff:=.2307315285-.1952872546;

y := 2321.533333
CumulativeConcentration

time = 72

:= 0.1952872546

dev := 2802.547574
UpperStd time = 72 := 0.2307315285

devDiff := 0.0354442739
case 16b: at time = 79 days, 107.4667 more area units were eluted.
> y:=2429;
CumulativeConcentration[time=79]:=(y+328.71)/13571;
dev:=2429+442.8970284;
UpperStd[time=79]:=(dev+328.71)/13571;
devDiff:=.2358416497-.2032061012;

y := 2429
CumulativeConcentration

time = 79

:= 0.2032061012

dev := 2871.897028
UpperStd time = 79 := 0.2358416497

devDiff := 0.0326355485
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case 17b: at time = 86 days, 76.73333 more area units were eluted.
> y:=2505.733333;
CumulativeConcentration[time=86]:=(y+328.71)/13571;
dev:=2505.733333+405.2431643;
UpperStd[time=86]:=(dev+328.71)/13571;
devDiff:=.2387212804-.2088603148;

y := 2505.733333
CumulativeConcentration

time = 86

:= 0.2088603148

dev := 2910.976497
UpperStd time = 86 := 0.2387212804

devDiff := 0.0298609656
case 18b: at time = 93 days, 57.06667 more area units were eluted.
> y:=2562.8;
CumulativeConcentration[time=93]:=(y+328.71)/13571;
dev:=2562.8+377.4835979;
UpperStd[time=93]:=(dev+328.71)/13571;
devDiff:=.2408808192-.2130653599;

y := 2562.8
CumulativeConcentration

time = 93

:= 0.2130653599

dev := 2940.283598
UpperStd time = 93 := 0.2408808192

devDiff := 0.0278154593
case 19b: at time = 100 days, 35.53333 more area units were eluted.
> y:=2598.333333;
CumulativeConcentration[time=100]:=(y+328.71)/13571;
dev:=2598.333333+355.7691199;
UpperStd[time=100]:=(dev+328.71)/13571;
devDiff:=.2418990828-.2156836882;
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y := 2598.333333
CumulativeConcentration

time = 100

:= 0.2156836882

dev := 2954.102453
UpperStd time = 100 := 0.2418990828

devDiff := 0.0262153946
case 20b: at time = 107 days, 30.86667 more area units were eluted.
> y:=2629.2;
CumulativeConcentration[time=107]:=(y+328.71)/13571;
dev:=2629.2+337.9609281;
UpperStd[time=107]:=(dev+328.71)/13571;
devDiff:=.2428613166-.2179581460;

y := 2629.2
CumulativeConcentration

time = 107

:= 0.2179581460

dev := 2967.160928
UpperStd time = 107 := 0.2428613166

devDiff := 0.0249031706
An average of 2629.2 area units were eluted which is equivalent to a total of
.2179581460 mg/ml.
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> restart;
> unprotect(D);
Program Diffusion through PLGA membrane Program
This program goes through the derivations necessary to obtain equation (12) and the
diffusion coefficient at each time interval.
case: Hollow cylinder of Infinite Length under steady state conditions with constant
concentration on each surface. Boundary Conditions:
@ r = Ri, C = Ci
@ r = Re, C = Ce
>
Variable declarations: Ri is the inner radius, the radius of the fiber.
Re is the outer radius, the radius of the PLGA coating.
r is the radius at any location in the composite, depends on
time.
D is the diffusion coefficient
L is the length of the coated fiber
t is the time
Mt is the amount of diffusing substance
V is the volume of the fiber
Ci is the dex21 fibers concentration
Ce is the concentration in the PLGA coated fiber
Steady State equations:
> Eq1:=diff(r*diff(C(r),r),r);
2
d
⎞
⎛d
⎛
⎞
⎜
Eq1 := ⎜⎜ C( r ) ⎟⎟ + r ⎜ 2 C( r ) ⎟⎟
d
r
⎝
⎠
⎝ dr
⎠
> Eq2:=dsolve(Eq1,C(r));
Eq2 := C( r ) = _C1 + _C2 ln( r )
> Eq3:=diff(Eq2,r);
Eq3 :=

d
_C2
C( r ) =
dr
r

Solving for using the boundary conditions previously stated.
> bc1:=_C2*ln(R[i])+_C1-C[i];
bc1 := _C2 ln( Ri ) + _C1 − Ci
> bc2:=_C2*ln(R[e])+_C1-C[e];
bc2 := _C2 ln( R e ) + _C1 − Ce
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> Eq4:=bc2-bc1;

Eq4 := _C2 ln( R e ) − Ce − _C2 ln( Ri ) + Ci

> solve(Eq4,_C2);
Ce − C i
ln( Re ) − ln( Ri )
Rewriting this result still in terms of what _C2 equals.
> _C2:=(C[e]-C[i])/ln(R[e]/R[i]);
_C2 :=

Ce − Ci
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

Substituting _C2 back into bc2 to solve for _C1.
> solve(bc2,_C1);
⎛ Re ⎞
−ln( Re ) Ce + ln( Re ) Ci + Ce ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠
R
⎛ e⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

Assigning these constants and substituting them into our intial Concentration equation.
> assign(_C1,_C2);
> Eq2;
C( r ) =

Ce − Ci
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

+

( Ce − Ci ) ln( r )
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

Rewriting these results yields:
> Eq2:=C(r)=C[e]+((C[e]-C[i])/ln(R[e]/R[i]))*ln(r/R[e]);
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r
( Ce − Ci ) ln⎛⎜ ⎞⎟
⎜ Re ⎟
⎝ ⎠
Eq2 := C( r ) = Ce +
R
⎛ e⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

>
The amount of a diffusing substance, M[t], diffuses through the length of the tubing in
time, t , can be calculated by integrating Fick's 1st Law w.r.t time.
> Eq4:=lhs(Eq3)=subs(r=R[e],rhs(Eq3));
Eq4 :=

d
C( r ) =
dr

Ce − C i
⎛ Re ⎞
ln⎜⎜ ⎟⎟ Re
⎜ Ri ⎟
⎝ ⎠

> Ficks:=-2*pi*R[e]*L*int((D*diff(C(r),r)),t);
d
Ficks := −2 π Re L D ⎜⎜⎛ C( r ) ⎟⎟⎞ t
⎝ dr
⎠

> M[t]:=subs(Eq4,Ficks);
Mt := −

2 π L D ( Ce − C i ) t
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

Since we have perfect sink conditions, Ce goes to 0.
> M[t]:=subs(C[e]=0,M[t]);
Mt :=

2 π L D Ci t
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

>
The purpose is to calculate D, the diffusion coefficient, so rearranging these equations:
> M[t]:=unapply(M[t]);
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Mt := ( ) →

2 π L D Ci t
⎛ Re ⎞
ln⎜⎜ ⎟⎟
⎜ Ri ⎟
⎝ ⎠

> D:=(M[t]*ln(R[e]/R[i]))/(2*Pi*L*C[i]*t);
⎛ Re ⎞
Mt ln⎜⎜ ⎟⎟
⎜ Ri ⎟
1
⎝ ⎠
D :=
2 π L Ci t

We shall now simplify this expression by making it a numerical expression and set it up
for each time interval by taking out the constants not affected by each interval.
The time for each case will be represented here by the variable n; however, the specific
cases do not follow a specific interval and therefore must be calculated individually.
Hours will be what n represents.
> D[n]:=A*M[t](n)/(C[i](n)*(t(n)-t(n-1)));
Dn :=

A π Mt
π Ci( n ) ( t( n ) − t( n − 1 ) )

Defining what variable A represents.
> A:=ln(R[e]/R[i])/(2*Pi*L);
⎛ Re ⎞
ln⎜⎜ ⎟⎟
1 ⎜⎝ Ri ⎟⎠
A :=
2 πL

Declaring the constants: Inner Radius, Ri; PLGA coated Radius, Re; L, length of the
coated fiber.
The inner radius, Ri is equal to the radius of the Dex21 collagen fiber before the coating.
This value was obtained from the volume fraction program for dexamethasone (the units
are in mm).
> R[i]:=0.05832;
R i := 0.05832
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The outer radius, Re is equal to the total radius with coating. Using the average of 30
fiber measurements we were able to obtain a total diameter average of 0.372333mm.
Therefore the radius would be 0.1861655mm.
> R[e]:=0.305667;
Re := 0.305667

The length of the coated fiber will be equal to the length of our fibers 10mm, plus the
thickness of the coating on the top and bottom of the fibers. The thickness is equal to the
radius of the PLGA. Solving for thickness (in mm), then length of the coated fiber, L
yields:
> PLGAthickness:= R[e]-R[i];

PLGAthickness := 0.247347
> L:= (PLGAthickness*2)+10;

L := 10.494694
Now we have all the components needed to solve for A (units are 1/mm).
> A:=ln(R[e]/R[i])/(2*evalf(Pi)*L);

A := 0.02512205784
I shall now convert this to centimeters for easier calculations later.
> A:=A/10;

A := 0.002512205784
The dex21 fibers concentration, Ci, is equal to the total concentration, Ct, minus the
dex21 eluted from the fibers.
Note: The total concentration was obtained from our previous experiments with just
Dex21 loaded fibers. This value is assumed to be the same since the fibers were
loaded exactly the same; the only difference is after loading they were coated with PLGA.
Here I will declare the total concentration
> C[tot]:=0.2220691179;
Ctot := 0.2220691179
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To calculate Mt, the amount of diffusing substance at each time, we must multiply the
concentration at that time (which has been previously calculated, refer to maple program,
Program Dexamethasone 21-phosphate Concentrations) by the volume of our PBS
solution, V[PBS] declared here. Units are milliliters.
> V[pbs]:=0.2;
V pbs := 0.2

Diffusion calculations at each time interval.
Units: Mt is in mg
Ci is in mg/ml
t is in seconds
D is in cm^2/sec
> unprotect(Ci);
Case1: At time 1 day.
> Mt[1]:= V[pbs]*.5157394444e-1;
Mt 1 := 0.01031478889

> Ci[1]:= C[tot]-.5157394444e-1;
Ci1 := 0.1704951735

> t[1]:=24*60*60;
t1 := 86400

> D[1]:=(A*Mt[1])/(Ci[1]*t[1]);
D1 := 0.1759096738 10 -8

Case2: At time 2 days.
> Mt[2]:= V[pbs]*.3426743298e-1;
Mt 2 := 0.006853486596
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> Ci[2]:= C[tot]-.6161987571e-1;
Ci2 := 0.1604492422

> t[2]:=86400;

t2 := 86400

> D[2]:=(A*Mt[2])/(Ci[2]*t[2]);
D2 := 0.1241982185 10 -8

Case3: At time 5 days.
> Mt[3]:= V[pbs]*.4057500061e-1;
Mt 3 := 0.008115000122

> Ci[3]:= C[tot]-.7797337460e-1;
Ci3 := 0.1440957433

> t[3]:=(86400*5-86400*2);
t3 := 259200

> D[3]:=(A*Mt[3])/(Ci[3]*t[3]);
D3 := 0.5458302404 10 -9

Case4: At time 8 days.
> Mt[4]:= V[pbs]*.3502886056e-1;
Mt 4 := 0.007005772112

> Ci[4]:= C[tot]-.8878073342e-1;
Ci4 := 0.1332883845
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> t[4]:=(86400*8-86400*5);
t4 := 259200

> D[4]:=(A*Mt[4])/(Ci[4]*t[4]);
D4 := 0.5094292955 10 -9

Case5: At time 12 days.
> Mt[5]:= V[pbs]*.3713629553e-1;
Mt 5 := 0.007427259106

> Ci[5]:= C[tot]-.1016955272;
Ci5 := 0.1203735907

> t[5]:=(86400*12-86400*8);
t5 := 345600

> D[5]:=(A*Mt[5])/(Ci[5]*t[5]);
D5 := 0.4485169259 10 -9

Case6: At time 17 days.
> Mt[6]:= V[pbs]*.3739174219e-1;
Mt 6 := 0.007478348438

> Ci[6]:= C[tot]-.1148657677;
Ci6 := 0.1072033502

> t[6]:=(86400*17-86400*12);
t6 := 432000
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> D[6]:=(A*Mt[6])/(Ci[6]*t[6]);
D6 := 0.4056661806 10 -9

Case7: At time 23 days.
> Mt[7]:= V[pbs]*.3890968486e-1;
Mt 7 := 0.007781936972

> Ci[7]:= C[tot]-.1295539508;
Ci7 := 0.0925151671

> t[7]:=(86400*23-86400*17);
t7 := 518400

> D[7]:=(A*Mt[7])/(Ci[7]*t[7]);
D7 := 0.4076289213 10 -9

Case8: At time 30 days.
> Mt[8]:= V[pbs]*.3975462383e-1;
Mt 8 := 0.007950924766

> Ci[8]:= C[tot]-.1450870729;
Ci8 := 0.0769820450

> t[8]:=(86400*30-86400*23);
t8 := 604800

> D[8]:=(A*Mt[8])/(Ci[8]*t[8]);
D8 := 0.4290141624 10 -9
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Case9: At time 37 days.
> Mt[9]:= V[pbs]*.3463095326e-1;
Mt 9 := 0.006926190652

> Ci[9]:= C[tot]-.1554965244;
Ci9 := 0.0665725935

> t[9]:=(86400*37-86400*30);
t9 := 604800

> D[9]:=(A*Mt[9])/(Ci[9]*t[9]);
D9 := 0.4321578381 10 -9

Case10: At time 44 days.
> Mt[10]:= V[pbs]*.3218947265e-1;
Mt 10 := 0.006437894530

> Ci[10]:= C[tot]-.1634644954;
Ci10 := 0.0586046225

> t[10]:=(86400*44-86400*37);
t10 := 604800

> D[10]:=(A*Mt[10])/(Ci[10]*t[10]);
D10 := 0.4563051953 10 -9

Case11: At time 51 days.
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> Mt[11]:= V[pbs]*.3098592587e-1;
Mt 11 := 0.006197185174

> Ci[11]:= C[tot]-.1702289195;
Ci11 := 0.0518401984

> t[11]:=(86400*51-86400*44);
t11 := 604800

> D[11]:=(A*Mt[11])/(Ci[11]*t[11]);
D11 := 0.4965594449 10 -9

Case12: At time 58 days.
> Mt[12]:= V[pbs]*.2989045268e-1;
Mt 12 := 0.005978090536

> Ci[12]:= C[tot]-.1758978704;
Ci12 := 0.0461712475

> t[12]:=(86400*58-86400*51);
t12 := 604800

> D[12]:=(A*Mt[12])/(Ci[12]*t[12]);
D12 := 0.5378167298 10 -9

Case13: At time 65 days.
> Mt[13]:= V[pbs]*.3376145212e-1;
Mt 13 := 0.006752290424
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> Ci[13]:= C[tot]-.1854378208;
Ci13 := 0.0366312971

> t[13]:=(86400*65-86400*58);
t13 := 604800

> D[13]:=(A*Mt[13])/(Ci[13]*t[13]);
D13 := 0.7656710823 10 -9

Case14: At time 72 days.
> Mt[14]:= V[pbs]*.3407093557e-1;
Mt 14 := 0.006814187114

> Ci[14]:= C[tot]-.1952872546;
Ci14 := 0.0267818633

> t[14]:=(86400*72-86400*65);
t14 := 604800

> D[14]:=(A*Mt[14])/(Ci[14]*t[14]);
D14 := 0.1056858135 10 -8

Case15: At time 79 days.
> Mt[15]:= V[pbs]*.3214034829e-1;
Mt 15 := 0.006428069658

> Ci[15]:= C[tot]-.2032061012;
Ci15 := 0.0188630167
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> t[15]:=(86400*79-86400*72);
t15 := 604800

> D[15]:=(A*Mt[15])/(Ci[15]*t[15]);
D15 := 0.1415509713 10 -8

Case16: At time 86 days.
> Mt[16]:= V[pbs]*.2987571537e-1;
Mt 16 := 0.005975143074

> Ci[16]:= C[tot]-.2088603148;
Ci16 := 0.0132088031

> t[16]:=(86400*86-86400*79);
t16 := 604800

> D[16]:=(A*Mt[16])/(Ci[16]*t[16]);
D16 := 0.1879006452 10 -8

Case17: At time 93 days.
> Mt[17]:= V[pbs]*0.2842654680e-1;
Mt 17 := 0.005685309360

> Ci[17]:= C[tot]-.2130653599;
Ci17 := 0.0090037580

> t[17]:=(86400*93-86400*86);
t17 := 604800
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> D[17]:=(A*Mt[17])/(Ci[17]*t[17]);
D17 := 0.2622851584 10 -8

Case18: At time 100 days.
> Mt[18]:= V[pbs]*.2683983003e-1;
Mt 18 := 0.005367966006

> Ci[18]:= C[tot]-.2156836882;
Ci18 := 0.0063854297

> t[18]:=(86400*100-86400*93);
t18 := 604800

> D[18]:=(A*Mt[18])/(Ci[18]*t[18]);
D18 := 0.3491910129 10 -8

Case19: At time 107 days.
> Mt[19]:= V[pbs]*.2649595952e-1;
Mt 19 := 0.005299191904

> Ci[19]:= C[tot]-.2179581460;
Ci19 := 0.0041109719

> t[19]:=(86400*107-86400*100);
t19 := 604800

> D[19]:=(A*Mt[19])/(Ci[19]*t[19]);
D19 := 0.5354372330 10 -8
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Displaying all the diffusion coefficients up to day 107 (Units m^2/s).
> for i from 1 by 1 to 19 do
D[i]*10^(-4);
end do;
0.1759096738 10 -12
0.1241982185 10 -12
0.5458302404 10 -13
0.5094292955 10 -13
0.4485169259 10 -13
0.4056661806 10 -13
0.4076289213 10 -13
0.4290141624 10 -13
0.4321578381 10 -13
0.4563051953 10 -13
0.4965594449 10 -13
0.5378167298 10 -13
0.7656710823 10 -13
0.1056858135 10 -12
0.1415509713 10 -12
0.1879006452 10 -12
0.2622851584 10 -12
0.3491910129 10 -12
0.5354372330 10 -12

>
Using Matlab to plot the diffusion coefficients versus time (figure 20), we were able to
calculate the steady-state diffusion rate. After 5 days the diffusion rate stabilizes till day
58, from here a linearization was taken. This provided us with an equation of:
y = 3.17e-22*x+4.59e-14
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where y is the diffusion coefficient and x is the time in seconds. The slope of the line can
be cancelled out since it is so minute. This provides us with a steady-state diffusion
coefficient of 4.59e-14 m^2/sec for diffusion of dexamethasone 21-phosphate through the
PLGA coating.
Note: The experimental data we used to calculate these results was only tested for 107
days. According to the data and trend the coated fibers should last slightly longer than
this. At 107 days, 98% of the dexamethasone 21-phosphate was eluted. Theoretically, as
the experiment continues to progress, the PLGA coating should begin to degrade more
rapidly allowing the remaining dexamethasone 21-phosphate to diffuse quicker. From the
diffusion results it appears this occurs. At about 65 days the PLGA coating may start to
degrade increasing the rate of diffusion. It seems shortly after 107 days all the
dexamethasone 21-phosphate loaded should have left the fiber.
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